Company Registration No. 14327803 (England and Wales)
Weymouth Pharma Ltd
Unaudited accounts
for the year ended 31 August 2024
Weymouth Pharma Ltd
Unaudited accounts
Contents
Weymouth Pharma Ltd
Company Information
for the year ended 31 August 2024
Directors
Sunil Varghese Chacko
Moyosoreoluwa Ogunfowoke
Company Number
14327803 (England and Wales)
Registered Office
19 Fuchsia Gardens
Southampton
SO16 6TY
United Kingdom
Weymouth Pharma Ltd
Statement of financial position
as at 31 August 2024
Intangible assets
625,080
233,094
Tangible assets
3,966
4,280
Cash at bank and in hand
27,363
30,733
Creditors: amounts falling due within one year
(409,954)
(227,265)
Net current liabilities
(139,709)
(55,049)
Total assets less current liabilities
489,337
182,325
Creditors: amounts falling due after more than one year
(488,000)
(181,210)
Called up share capital
100
100
Profit and loss account
1,237
1,015
Shareholders' funds
1,337
1,115
For the year ending 31 August 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with the provisions of FRS 102 Section 1A - Small Entities. The profit and loss account has not been delivered to the Registrar of Companies.
The financial statements were approved by the Board of Directors and authorised for issue on 10 May 2025 and were signed on its behalf by
Sunil Varghese Chacko
Director
Company Registration No. 14327803
Weymouth Pharma Ltd
Notes to the Accounts
for the year ended 31 August 2024
Weymouth Pharma Ltd is a private company, limited by shares, registered in England and Wales, registration number 14327803. The registered office is 19 Fuchsia Gardens, Southampton, SO16 6TY, United Kingdom.
2
Compliance with accounting standards
The accounts have been prepared in accordance with the provisions of FRS 102 Section 1A Small Entities. There were no material departures from that standard.
The principal accounting policies adopted in the preparation of the financial statements are set out below and have remained unchanged from the previous year, and also have been consistently applied within the same accounts.
The accounts have been prepared under the historical cost convention as modified by the revaluation of certain fixed assets.
The accounts are presented in £ sterling.
Intangible fixed assets (including purchased goodwill and patents) are included at cost less accumulated amortisation.
Tangible fixed assets and depreciation
Tangible assets are included at cost less depreciation and impairment. Depreciation has been provided at the following rates in order to write off the assets over their estimated useful lives:
Computer equipment
20% reduce balance basis
4
Intangible fixed assets
Goodwill
At 1 September 2023
237,045
Weymouth Pharma Ltd
Notes to the Accounts
for the year ended 31 August 2024
5
Tangible fixed assets
Computer equipment
Amounts falling due within one year
Trade debtors
112,915
38,119
7
Creditors: amounts falling due within one year
2024
2023
Trade creditors
153,002
44,312
Taxes and social security
2,335
1,247
Other creditors
14,856
9,982
Loans from directors
239,761
171,524
8
Creditors: amounts falling due after more than one year
2024
2023
Bank loans
488,000
181,210
9
Average number of employees
During the year the average number of employees was 14 (2023: 4).